Bullish case
$355 to $385
More likely if Skyrizi and Rinvoq keep compounding, neuroscience keeps growing, the Apogee pipeline delivers, and investors value AbbVie near 19 to 20x forward adjusted EPS.
AbbVie Inc. research snapshot
ABBV AI Stock Analysis
ABBV AI stock analysis reads AbbVie Inc. as a large-cap biopharma company with durable immunology and neuroscience growth, a shrinking Humira drag, a fresh $10.9 billion Apogee Therapeutics acquisition, high debt, and a valuation that already assumes continued execution. At the August 2, 2026 data cutoff, ABBV closed near $250.94 on July 31, 2026, the session after its second-quarter earnings, with an implied market capitalization of about $443 billion. This page uses scenarios, technical levels, and source-backed facts. It is informational research, not investment advice.
Current price
$250.94
Market cap
$443 billion
AI score
74 / 100
Rating
High-quality pharma compounder at a full valuation
Trend status
Uptrend intact after a short-term post-earnings pullback
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
Research quality check
- information Richness
- A-level information richness. AbbVie has long public filings, detailed product revenue tables, quarterly releases, dense technical coverage, and broad analyst attention from about 31 covering analysts.
- bias Check
- The main AI bias risk is over-weighting the visible Skyrizi, Rinvoq, and neuroscience growth story while under-weighting biosimilar pressure, oncology decline, the dilutive Apogee acquisition, debt, and multiple risk after a strong run.
- ai Confidence
- High for filings, Q2 2026 reported metrics, market cap math, and technical snapshots. Medium for forward valuation because drug adoption, patent cycles, approvals, integration, and payer pressure can shift quickly.
- investment Certainty
- Medium. The business quality is easier to identify than the margin of safety at the current price.
Quick verdict table
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | AbbVie sells patented medicines and aesthetics products across immunology, neuroscience, oncology, eye care, and Allergan Aesthetics, with chronic disease franchises that generate recurring revenue. | High |
| Moat | The moat comes from patents, clinical evidence, physician familiarity, payer access, regulatory expertise, global scale, and a broad commercial infrastructure, but it narrows as exclusivity expires. | Medium-high |
| Management | Robert A. Michael has navigated the post-Humira transition well; future judgment depends on capital allocation, the Apogee integration, pipeline productivity, debt reduction, and dividend durability. | Medium |
| Financial trend | FY2025 revenue rose 8.6% to $61.160 billion, Q2 2026 revenue rose 10.2% to $16.990 billion, and Q2 2026 adjusted EPS rose 22.9% to $3.65 as Skyrizi, Rinvoq, and neuroscience offset Humira decline. | High |
| Valuation | Using the updated 2026 adjusted EPS guidance midpoint near $13.97, ABBV traded near 17.96x forward adjusted EPS and 22.19x TTM free cash flow per share at the July 31, 2026 close. | Medium-high |
| Technical trend | The price held above the 50-day and 200-day moving averages but slipped below the 20-day after a two-day drop around earnings, with a neutral 14-day RSI near 51.11. | Medium |
| Risk level | Main risks are drug concentration, biosimilar erosion, oncology decline, payer pressure, Apogee integration, litigation or regulatory changes, and high debt near $72.9 billion. | Medium-high |
| AI confidence | High for descriptive research and calculations. Lower for exact price outcomes because drug stocks reprice quickly around data, approvals, and integration news. | High data confidence |
| Investment certainty | Medium certainty. ABBV is high quality, but a buy decision depends on price discipline and the ability to underwrite patent-cycle, biosimilar, and integration risk. | Medium |
ABBV AI stock forecast
ABBV AI Stock Forecast Scenarios
The ABBV AI stock forecast uses scenario math around the July 31, 2026 close of $250.94 and the 2026 adjusted EPS guidance midpoint of $13.97. Over a three-year horizon, the framework produced a bearish area near $195 to $205, a base area near $265 to $290, and a bullish area near $355 to $385 before dividends.
Base case
$265 to $290
More likely if adjusted EPS compounds in the high single digits and investors value AbbVie near a 16 to 17x earnings multiple while debt and biosimilar risk stay manageable.
Bearish case
$195 to $205
More likely if immunology growth slows, oncology keeps declining, Apogee integration disappoints, payer pressure cuts pricing, or investors compress the multiple toward 13x.
ABBV AI technical analysis
ABBV AI Technical Analysis
ABBV AI technical analysis is constructive but not risk-free as of the July 31, 2026 close. Barchart data showed the price above the 50-day moving average near $238.07 and the 200-day moving average near $224.69, below the 20-day moving average near $253.84, a neutral 14-day RSI near 51.11, and a 14-day ATR near $6.64.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $250.94 | July 31, 2026 close, the session after Q2 2026 earnings. Used for market cap math at the August 2, 2026 cutoff. |
| Near resistance | $253.8 to $260 | The 20-day moving average near $253.84 and the July 30 swing high near $259.86 cap the first recovery zone. |
| Upper resistance | $263 to $267 | The prior close area near $263.30 and the 52-week high near $267.47 are the stronger overhead levels. |
| Near support | $250 to $248 | A psychological round number plus the breakout zone where buyers stepped in during the pullback. |
| 50-day moving average | $238.07 | Barchart showed the price still about 5% above the 50-day moving average, keeping the medium-term trend intact. |
| 200-day moving average | $224.69 | The price remained well above the 200-day moving average, supporting the long-term uptrend. |
| Momentum | 14-day RSI 51.11 | RSI was neutral. Short-term stochastics cooled from overbought readings after the two-day drop. |
| Volume | About 6.4 million shares on July 31 | Modestly above the roughly 5.8 million to 6.8 million 20-day average, with activity elevated around the earnings release. |
| Volatility | 14-day ATR about $6.64 | Near a 2.6% average daily range, with 14-day historic volatility around 25% to 28%. Expect larger moves around clinical and regulatory events. |
| Invalidation | Close below $238, then $224.69 | A decisive break below the 50-day moving average would weaken the medium-term setup. A break below the 200-day moving average would be more serious. |
ABBV AI trading strategy
ABBV AI Trading Strategy Framework
The ABBV AI trading strategy is a rules-based research framework for a high-quality but fully valued biopharma compounder. It is not personal advice and should be paired with live quotes, filings, position sizing, and clinical, regulatory, and integration event checks.
Trend-following setup
Watch for ABBV to reclaim the 20-day moving average near $253.84 and clear the $259.9 to $260 resistance zone with volume confirmation.
A close back below the 50-day moving average near $238, or a failed reclaim after earnings, guidance, or clinical news, should invalidate the short-term setup.
Mean-reversion setup
If ABBV extends the pullback toward the 50-day moving average near $238 without a new product, pipeline, or guidance problem, compare the price reaction with Skyrizi, Rinvoq, and neuroscience growth evidence.
Do not average down without a defined loss limit because drug-specific news can turn a support level into a thesis break.
Fundamental monitor
Track immunology revenue, Humira erosion, oncology decline, adjusted operating margin, free cash flow, debt maturities, dividend coverage, pipeline readouts, and Apogee integration progress.
Reduce confidence if adjusted EPS growth depends mainly on adjustments, buybacks, or multiple expansion rather than durable product-level revenue and cash flow.
Investment research summary
Four-master Research Compression
Business essence
AbbVie converts drug discovery, regulatory approvals, physician adoption, and payer access into recurring global medicine revenue across immunology, neuroscience, oncology, and aesthetics.
Moat
The moat is strongest where patents, clinical evidence, prescriber trust, reimbursement access, and commercial scale reinforce each other. It narrows when exclusivity expires or rivals show better efficacy, safety, or convenience.
Munger risk inversion
The thesis fails if Skyrizi and Rinvoq growth slows, oncology keeps declining, biosimilar or payer pressure reduces pricing power, the Apogee integration disappoints, or debt and acquisitions consume owner earnings.
Management
Management has executed the post-Humira transition better than many feared, but future judgment depends on capital allocation, the Apogee integration, pipeline productivity, balance sheet discipline, and dividend coverage.
Industry trend
Biopharma benefits from aging populations, unmet medical need, and innovation, but the industry faces patent cliffs, price scrutiny, regulatory uncertainty, and binary clinical outcomes.
Valuation and margin of safety
ABBV is not priced as a distressed patent-cliff story. Margin of safety depends on whether adjusted EPS can compound despite competition, the Apogee dilution, debt, and normal pharma setbacks.
Source-backed data
ABBV Data Table
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| ABBV price | $250.94 | StockAnalysis quote snapshot, Yahoo Finance cross-check | August 2, 2026 |
| Market capitalization | $443.36 billion, verified as $250.94 x about 1.767 billion shares | StockAnalysis statistics and price-times-shares verification | August 2, 2026 |
| Q2 2026 revenue and adjusted EPS | $16.990 billion revenue (+10.2% reported), $3.65 adjusted diluted EPS (+22.9%) | AbbVie Q2 2026 earnings release | August 2, 2026 |
| Q2 2026 GAAP EPS | $2.03, up 290.4% on low prior-year IPR&D charges | AbbVie Q2 2026 earnings release | August 2, 2026 |
| 2026 adjusted EPS guidance | $13.87 to $14.07, midpoint $13.97, after Q2 update and $0.14 Apogee dilution | AbbVie Q2 2026 earnings release | August 2, 2026 |
| FY2025 revenue and GAAP net earnings | $61.160 billion revenue (+8.6%), $4.226 billion GAAP net earnings | AbbVie 2025 Form 10-K via StockAnalysis financials | August 2, 2026 |
| TTM revenue and GAAP EPS | $64.386 billion revenue, $3.54 GAAP diluted EPS through Q2 2026 | StockAnalysis financials | August 2, 2026 |
| Cash, debt, and net debt | $9.391 billion cash and investments, $72.858 billion total debt, about $63.5 billion net debt as of March 31, 2026. Year-end 2025 10-K figures differ, so date context matters. | StockAnalysis balance sheet | August 2, 2026 |
| Apogee Therapeutics acquisition | About $10.9 billion total equity value, expected to close in Q3 2026 | AbbVie Q2 2026 earnings release | August 2, 2026 |
| Valuation check | 17.96x 2026 adjusted EPS guidance midpoint, 70.89x trailing GAAP EPS, 22.19x TTM free cash flow per share, 2.76% dividend yield ($6.92) | StockAnalysis statistics and price-times-multiple verification | August 2, 2026 |
| Technical snapshot | 20-day MA $253.84, 50-day MA $238.07, 200-day MA $224.69, 14-day RSI 51.11 | Barchart technical analysis | August 2, 2026 |
| Dividend track record | $6.92 annualized dividend with 54 consecutive years of increases | StockAnalysis dividend data and AbbVie communications | August 2, 2026 |
Frequently Asked Questions
Read the MMM AI stock analysisView T AI stock forecastExplore NVDA AI technical analysisCompare ideas in AI Stock PickerBuild a rules-based trading strategyScreen stocks with Pineify
This ABBV AI stock analysis is an informational research tool, not investment advice, a recommendation, or a promise of future return. Forecast ranges are scenarios based on available filings, quote snapshots, technical data, and third-party sources as of the stated cutoff date. They may be wrong, incomplete, or outdated after new earnings, clinical data, regulatory events, acquisitions, market moves, or macro conditions.
Related Tools
Trading Strategy Builder
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Open
Stock Screener
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Open
AI Stock Picker & Screener
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
Open